Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Eliem Therapeutics (ELYM).
Aoife Brennan has been appointed as the President and CEO of Eliem, and will serve as a member of the board until the 2027 annual stockholders meeting. Bringing extensive biotech management experience and a notable track record from her previous roles at Synlogic, Inc. and Biogen Inc., where she led the approval of several major drugs, Dr. Brennan is well-positioned to steer Eliem through its next phases of growth. Her compensation includes a $650,000 base salary, potential bonuses, stock options, and other benefits. Additionally, Stephen Thomas, CEO of Tenet, has been elected to Eliem’s board, with expectations of further contribution as a consultant post-Acquisition. These strategic appointments come amidst Eliem’s significant acquisition activities and are critical for investors monitoring the company’s leadership and direction.
Learn more about ELYM stock on TipRanks’ Stock Analysis page.